Stock A288330 BRIDGE BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Bridge Biotherapeutics, Inc.

Equities

A288330

KR7288330004

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 30/05/2024 BST 		5-day change 1st Jan Change
2,315 KRW +10.24% Intraday chart for Bridge Biotherapeutics, Inc. +9.72% -29.53%
03-28 Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade CI
03-26 Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade
Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology
Bridge Biotherapeutics, Inc. announced that it has received KRW 1.99999872 billion in funding
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 1.99999872 billion in funding
Gpcr Therapeutics, Inc. Collaborates with Bridge Biotherapeutics, Inc. to Pursue Joint Development and Commercialization of the Combination Therapy
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
Bridge Biotherapeutics, Inc.(KOSDAQ:A288330) dropped from S&P Global BMI Index
Bridge Biotherapeutics to Present at the 2023 BIO International Convention
Bridge Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Bridge Biotherapeutics Inc. Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis
Bridge Biotherapeutics announces preclinical study of self-discovered 4th generation lung cancer targeted therapy at AACR conference in the US
Bridge Biotherapeutics Presents Phase 2A Clinical Trial Results for BBT-401
Bridge Biotherapeutics, Inc. Initiates Phase 2 Clinical Trial of BBT-877 in Patients with Idiopathic Pulmonary Fibrosis
Bridge Biotherapeutics, Inc. Presents Non-Clinical Study Results for 2 IPF Candidates at the IPF Summit 2022
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877
Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022
Bridge Biotherapeutics : Material Management Information related to Judgment of Investment (US FDA approval of BBT-877 phase 2 clinical trial plan for the treatment of Idiopathic Pulmonary Fibrosis (IPF))
Bridge Biotherapeutics : Organization of Investor Relations Event
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A288330 Stock
  4. News Bridge Biotherapeutics, Inc.
  5. Other languages